Bicycle Therapeutics Ltd

Stock Chart, Company Information, and Scan Results

$7.12(as of Sep 9, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Bicycle Therapeutics Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$7.12
Ticker SymbolBCYC
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees305
CountyUSA
Market Cap$496.2M
EBIDTA-281.1M
10-Day Moving Average7.10
P/E Ratio-2.00
20-Day Moving Average7.19
Forward P/E Ratio0.00
50-Day Moving Average7.64
Earnings per Share-3.52
200-Day Moving Average10.55
Profit Margin-2,703.84%
RSI40.85
Shares Outstanding49.9M
ATR0.39
52-Week High28.67
Volume201,509
52-Week Low6.10
Most Recent Support Level6.75
Book Value668.9M
Most Recent Resistance Level7.64
P/B Ratio0.72
Upper Keltner8.06
P/S Ratio25.14
Lower Keltner6.32
Debt-to-Equity Ratio8.06
Next Earnings Date10/29/2025
Cash Surplus644.0M
Next Ex-Dividend DateUnknown

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics Ltd In Our Stock Scanner

As of Sep 09, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Double BottomScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.